Breakthrough trial aims to free kidney patients from lifelong medications
NCT ID NCT00619528
Summary
This study tested a new approach to help kidney transplant patients stop taking lifelong anti-rejection drugs. It involved 88 patients who received a kidney from a genetically matched sibling. The treatment combined a special medication (Campath-1H) with infusions of the donor's stem cells, with the goal of safely stopping all immunosuppressive drugs one year after the transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.